The US Food and Drug Administration (FDA) has approved lenacapavir as a long-acting injectable drug to prevent HIV.

Kymera’s programme focuses on removing CDK2 from cells compared to other therapies that target the protein’s inhibition.

Discover how young healthcare innovators from Durban are transforming clinical trials and community health, earning accolades from the South African Medical Research Council for their groundbreaking ...

The US has approved lenacapavir for HIV prevention. However, experts worry that cuts to the health budget will "squander" the drug's chance of reducing infections.